Updating results

1027 results

Sort: Relevance | Date

Alitretinoin for the treatment of severe chronic hand eczema (TA177)

Evidence-based recommendatrions on alitretinoin (Toctino) for treating severe chronic hand eczema in adults

Technology appraisal guidance Published August 2009

Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published June 2010 Last updated August 2017

Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)

Evidence-based recommendations on rituximab (MabThera) for treating relapsed or refractory chronic lymphocytic leukaemia (CLL)

Technology appraisal guidance Published July 2010

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

Evidence-based recommendations on continuous subcutaneous insulin infusion for the treatment of diabetes mellitus

Technology appraisal guidance Published July 2008

Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) (TA149)

NICE is unable to make a recommendation about the use in the NHS of carmustine implants because no evidence submission was received from the

Technology appraisal guidance Published June 2008

Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)

NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published June 2008

Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139)

Evidence-based recommendations on continuous positive airway pressure (CPAP) for the treatment of obstructive sleep apnoea/hypopnoea syndrome

Technology appraisal guidance Published March 2008

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (TA137)

Evidence-based recommendations on rituximab (MabThera) for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma

Technology appraisal guidance Published February 2008

Structural neuroimaging in first-episode psychosis (TA136)

Evidence-based recommendations on structural neuroimaging for treating first-episode psychosis

Technology appraisal guidance Published February 2008

Pemetrexed for the treatment of non-small-cell lung cancer (TA124)

Evidence-based recommendations on pemetrexed (Alimta) for treating non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published August 2007

Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)

Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer

Technology appraisal guidance Published January 2007 Last updated January 2012

Stapled haemorrhoidopexy for the treatment of haemorrhoids (TA128)

Evidence-based recommendations on stapled haemorrhoidopexy for treating haemorrhoids

Technology appraisal guidance Published September 2007

Infliximab for the treatment of adults with psoriasis (TA134)

Evidence-based recommendations on infliximab (Remicade) for treating psoriasis in adults

Technology appraisal guidance Published January 2008

Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over (TA138)

Evidence-based recommendations on onhaled corticosteroids for treating chronic asthma in adults and children aged 12 years and over

Technology appraisal guidance Published March 2008

Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

Evidence-based recommendations on aripiprazole (Abilify) for treating moderate to severe manic episodes in adolescents with bipolar I disorder

Technology appraisal guidance Published July 2013

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)

Evidence-based recommendations on tocilizumab (RoActemra) for treating systemic juvenile idiopathic arthritis

Technology appraisal guidance Published December 2011

Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)

NICE is unable to recommend the use in the NHS of panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer..

Technology appraisal guidance Published December 2011 Last updated March 2017

Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)

Evidence-based recommendations on rituximab (MabThera) for the first-line treatment of stage III–IV follicular lymphoma

Technology appraisal guidance Published January 2012

Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)

Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced (unresectable or metastatic) melanoma

Technology appraisal guidance Published December 2012

Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion

Technology appraisal guidance Published May 2013

Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)

Evidence-based recommendations on the use of fludarabine for B-cell chronic lymphocytic leukaemia (CLL)

Technology appraisal guidance Published September 2001

Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)

Evidence-based recommendations on streptokinase (Streptase), alteplase (Actilyse), reteplase (Rapilysin) and tenecteplase (Metalyse) for early thrombolysis in

Technology appraisal guidance Published October 2002

Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)

Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis (CF)

Technology appraisal guidance Published November 2012

Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)

Evidence-recommendations on erythropoiesis-stimulation agents (epoetin alfa, beta, theta and zeta and darbepoetin alfa) for anaemia in people with cancer..

Technology appraisal guidance Published November 2014

Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (TA328)

NICE is unable to make a recommendation about use in the NHS of idelalisib for follicular lymphoma refractory to 2 prior treatments..

Technology appraisal guidance Published December 2014

Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

HST1 Eculizumab for treating atypical haemolytic uraemic syndrome 1 Guidance 1.1 Eculizumab, within its marketing

Technology appraisal guidance

Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis (MS/RRMS)

Technology appraisal guidance Published August 2014

Mirabegron for treating symptoms of overactive bladder (TA290)

Evidence-based recommendations on mirabegron (Betmiga) for treating the symptoms of overactive bladder

Technology appraisal guidance Published June 2013

Laparoscopic surgery for colorectal cancer (TA105)

Evidence-based recommendations on laparoscopic surgery for colorectal (bowel) cancer

Technology appraisal guidance Published August 2006

Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)

Evidence-based recommendations on docetaxel (Taxotere) for the treatment of hormone-refractory metastatic (advanced) prostate cancer

Technology appraisal guidance Published June 2006

Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)

Evidence-based recommendations on the use of inhaler systems (devices) for chronic asthma in children under 5

Technology appraisal guidance Published August 2000

Guidance on the Extraction of Wisdom Teeth (TA1)

Evidence-based recommendations on the extraction of wisdom teeth

Technology appraisal guidance Published March 2000

Methadone and buprenorphine for the management of opioid dependence (TA114)

Evidence-based recommendations on methadone and buprenorphine for the management of opioid dependence

Technology appraisal guidance Published January 2007

Infliximab for acute exacerbations of ulcerative colitis (TA163)

Evidence-based recommendations on infliximab (Remicade) for acute exacerbations of ulcerative colitis in adults

Technology appraisal guidance Published December 2008

Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)

Evidence-based recommendations on pemetrexed (Alimta) for treating malignant pleural mesothelioma (cancer)

Technology appraisal guidance Published January 2008

Bortezomib monotherapy for relapsed multiple myeloma (TA129)

Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma (bone marrow cancer)

Technology appraisal guidance Published October 2007

Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)

Evidence-based recommendations on natalizumab (Tysabri) for highly active relapsing–remitting multiple sclerosis (MS) in adults

Technology appraisal guidance Published August 2007

Varenicline for smoking cessation (TA123)

Evidence-based recommendations on varenicline (Champix) to help people stop smoking

Technology appraisal guidance Published July 2007

Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273)

NICE is unable to make a recommendation about the use in the NHS of tadalafil for treating symptoms associated with benign prostatic hyperplasia...

Technology appraisal guidance Published January 2013

Ranibizumab for treating diabetic macular oedema (TA274)

Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema

Technology appraisal guidance Published February 2013

Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)

Evidence-based recommendations on vinflunine (Javlor) for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

Technology appraisal guidance Published January 2013

Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) (TA270)

NICE is unable to make a recommendation about the use in the NHS of decitabine for the treatment of acute myeloid leukaemia because no evidence...

Technology appraisal guidance Published December 2012

Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease (TA20)

Evidence-based recommendations on the use of Riluzole (Rilutek) for treating motor neurone disease (MND)

Technology appraisal guidance Published January 2001

Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)

Evidence-based recommendations on imatinib (Glivec) for treating unresectable (inoperable) and/or metastatic gastrointestinal stromal tumours (GISTs)

Technology appraisal guidance Published November 2010

Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

Evidence-based recommendations on bevacizumab (Avastin) with oxaliplatin and fluorouracil plus folinic acid or capecitabine for metastatic colorectal cancer

Technology appraisal guidance Published December 2010

Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) (TA207)

NICE is unable to make a recommendation about the use in the NHS of temsirolimus for treating relapsed or refractory mantle cell lymphoma because no evidence

Technology appraisal guidance Published October 2010

Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia

Technology appraisal guidance Published November 2013